The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases
30572 Neurology Summit Assets 21 R0231024X512 Final

Landmark biomarker and prevention studies, and hypothetical models of preclinical neurodegenerative diseases have been reported in The Lancet and The Lancet Neurology over the past decade. Reflecting our commitment to support this crucial area of neurological research, this Summit will provide a timely update on the latest advances and challenges in this area, with an emphasis on prevention.

The Summit will also provide a forum for discussion of the ethical and regulatory issues that these advances will bring about in research settings and clinical practice.

The programme will cover these topics:

  • Genetics, cellular pathways, and neuronal vulnerability
  • Biomarkers and early diagnosis
  • Prevention through therapeutics
  • Ethical and regulatory considerations

This event is sponsored by the UK Dementia Research Institute

More information

Founding funders

Latest tweets from @UKDRI

RT @medicmoritz: Very pleased to share our recent review on blood-CNS barrier dysfunction in amyotrophic lateral sclerosis in @_JCBFM: http…
27 Jan 2023 12:17

Huge congratulations to @JuliaZbiegly, @nlconnor_robson & @DrMcglasson who have been awarded funding through our Co… https://t.co/OGOiSgWKro
27 Jan 2023 12:01